ImClone news from FiercePharma
NewsImClone asks JPMorgan for deal advice
ImClone may have rejected Bristol-Myers Squibb's buyout advances so far, but now the company is hiring a Read more...
Did BMS bid to avoid ImClone dispute?
When Bristol-Myers Squibb announced its bid to buy its partner ImClone, a lot of people asked, Why now? ImClone's stock is a lot higher now than it was a couple of years ago. So if BMS didn't make an Read more...
Analysts: BMS lowballing ImClone
Who would you lay bets on: Carl Icahn or Jim Cornelius? The Bristol-Myers Squibb CEO has Read more...
Icahn throws wrench into ImClone offer
Carl Icahn has spoken--and he's not satisfied. Bristol-Myers Squibb's $4.5 billion bid for ImClone, he says, is too Read more...
BMS bid triggers deal talk
Have you noticed that one deal announcement inevitably leads to speculation of another? Well, yesterday's bombshell that Read more...
BMS bids $4.5B for ImClone
SPOTLIGHT: BMS bids $4.5B for ImCloneThey're partners on the cancer med Erbitux, so why not join forces completely? Bristol-Myers Squibb has offered $4.5 billion for ImClone Systems, a $60-per-share Read more...
Costs put cancer docs in financial bind
Pricey cancer meds aren't just putting the squeeze on patients and insurers. They're putting oncologists in a financial quandary as well. We got an inkling of this recently when the American Society Read more...
ASCO already churning out news
Today marks the start of the annual American Society of Clinical Oncology meeting, always a big news generator in the pharma biz. We'll let our sister pub FierceBiotech keep you up to date on the Read more...
Pfizer kills off Exubera, hunts for deals
It's official: Pfizer is giving up on Exubera. Pulling its plug cost the company $2.8 Read more...
ImClone: Stock buy timing a coincidence
Talk about great timing: new ImClone CEO John Johnson (formerly, yes, of Johnson Read more...
| Press ReleasesPRESS RELEASE: ImClone and BMS Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX in Japan ImClone Systems and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX in Japan NEW YORK, Oct. 17 -- ImClone Systems Incorporated and Read more... PRESS RELEASE: ImClone Systems Says Broader US Label for Erbitux Colorectal Cancer Drug ImClone Systems Says Broader US Label for Erbitux Colorectal Cancer Drug NEW YORK, Oct. 2 -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced that the U.S. Food and Read more... PRESS RLEASE: Repligen Announces Settlement with ImClone in Erbitux Lawsuit Repligen Announces Settlement with ImClone in Erbitux Lawsuit WALTHAM, MA - September 10, 2007 - Repligen Corporation announced today it has reached a settlement with ImClone Systems, Incorporated Read more... PRESS RELEASE: ImClone's ERBITUX Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study ImClone's ERBITUX Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study; Shares Soar NEW YORK -- ImClone Systems Incorporated and Bristol-Myers Squibb Company (NYSE: BMY - Read more... |
Get more ImClone coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets